Prospective, randomized, multicentre study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and/or worsening of previous vertebral fractures in women with a clinical vertebral fracture or recent hip fracture (imminent risk of fracture) caused by bone fragility.
This research is looking at two medicines, Terrosa and alendronate, which are used to make bones stronger. The study aims to find out which of these treatments is more effective at preventing new breaks in the bones of the spine (called vertebral fractures), or stopping existing ones from getting worse. We are focusing on women who have already experienced a break in their spine or a recent hip fracture caused by weak bones, as they are at high risk of more fractures. Over a year, doctors will monitor participants to see how the treatments affect their bones, using X-rays to check for any new spinal fractures or changes to old ones. The goal is to provide better long-term care for people with fragile bones.
At a glance
What is this study about?
Imagine your bones are like a building's structure; sometimes, they can become weak and more likely to break. This study is for women whose bones have become fragile, leading to a recent break in their spine or hip. Because they've had one fracture, they're at a higher risk of having more.
Doctors want to find the best way to prevent these future breaks, especially in the spine. This study compares two different medicines: Terrosa and alendronate. Both medicines are designed to strengthen bones, but doctors want to see which one works better over 52 weeks (about one year) to stop new spinal fractures from happening or to prevent old ones from getting worse. They will be carefully checking participants' spines using special X-rays.
This research is important because it could help doctors choose the best treatment for women at high risk of fractures, allowing them to lead healthier, more active lives with stronger bones. By understanding which treatment is more effective, we can improve how we care for people with bone fragility, reducing their chances of painful and life-altering fractures.
Key takeaways
- Compares two bone-strengthening medicines: Terrosa and alendronate.
- Aims to prevent new or worsening spinal fractures in women.
- Participants have recently had a fracture due to fragile bones.
- The study lasts for one year with regular check-ups and X-rays.
- Could help doctors choose better treatments for bone weakness.
- Your health and safety are the top priorities throughout the study.
Who may be eligible?
This study is specifically designed for women. To join, you must have recently experienced a fracture in your spine or a hip fracture that happened because your bones are fragile. This means you are considered to be at a higher risk of future breaks.
There are no age limits mentioned for this study, so women of many different ages could potentially take part, as long as they meet the other requirements. Your doctor would help determine if this study is a good fit for you based on your medical history and current health.
Remember, your safety and well-being are always the top priority. Clinical studies have strict rules about who can participate to ensure the research is safe and provides clear results. If you're interested, your doctor will review all the requirements with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you female?
- Have you recently experienced a fracture in your spine?
- Have you recently experienced a hip fracture caused by weak bones?
- Are you considered at a high risk of having more fractures?
What does participation involve?
If you decide to take part in this study, you'll be assigned to receive one of two study medicines: either Terrosa (given by injection using a special pen) or alendronate (a tablet). The study will last for 52 weeks, which is about one year.
During this year, you would have regular visits to the clinic. At these visits, doctors and nurses would perform various checks. This includes taking X-rays of your spine (upper back and lower back) at the beginning and end of the study to look for any changes in your spine bones. They will be looking to see if new fractures have occurred or if any existing ones have gotten worse. You will also be asked about any pain you might be experiencing and how your quality of life is, perhaps by filling out questionnaires. Your bone density will also be measured. Doctors will keep a close eye on your health, noting any side effects or changes to your well-being. Attending all visits and taking your medicine as advised are key parts of participating.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What kind of fractures is this study looking at?
The study is focused on preventing new breaks in the bones of your spine (vertebral fractures) or stopping existing spinal fractures from getting worse.
How long will the study last if I join?
The study will last for 52 weeks, which is approximately one year.
What medicines are being studied?
The study is comparing two medicines: Terrosa, given by injection, and alendronate, which is a tablet.
Will I know which medicine I'm getting?
This is a 'randomized' study, meaning you'll be assigned to one of the treatments by chance. In some studies, participants don't know which treatment they are receiving, but the study team will explain this to you.
Who can take part in this study?
This study is for women who have had a recent spinal fracture or a hip fracture due to weak bones, and who are at a higher risk of future fractures.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.